EVALUATION OF THE MUTAGENIC EFFECT OF THE DRUG SUBMASTIN-KRS

Abstract

In this research, we studied the potential mutagenic and toxic effects of the drug Submastin-KRS, which contains a mixture of species-specific bovine recombinant cytokines and vitamin A as active ingredients, on the body of white laboratory outbred mice (n=48). The animals were divided into 8 groups, 6 individuals in each one. A single injection of Submastin-KRS at a therapeutic and high dose (1/10 of LD50) did not lead to a statistically significant increase in the frequency of polymorphonuclear erythrocytes (PCE) with micronuclei and a decrease in the proportion of PCE in the bone marrow of the mice. The combined administration of Submastin-KRS and experimental mutagens (dioxidin, mitomycin C) it also caused neither potentiation of mutagenic activity nor a decrease in the frequency of PCE with micronuclei. Fourfold administration of Submastin-KRS at a high dose with an interval of 24 hours before the injection of mitomycin C had an antitoxic effect that was expressed in a statistically significant increase in the proportion of PCE in the bone marrow, relative to mice that received only mitomycin C. A similar administration of dioxidine together with Submastin-KRS did not lead to differences in the proportion of PCE relative to this indicator with the introduction of dioxidine alone. Thus, Submastin-KRS showed no mutagenic and toxic properties in relation to mouse bone marrow cells and also had an antitoxic effect in mitomycin-induced suppression of hematopoiesis that may serve as the evidence of its safety.